Related Experiment Video
Updated: Mar 25, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Identification of potential therapeutic targets for papillary thyroid carcinoma by bioinformatics analysis
Ming Zhao1, Ke-Jing Wang1, Zhuo Tan1
1Department of Head and Neck Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.
Abstract:
The aim of the present study was to identify potential therapeutic targets for papillary thyroid carcinoma (PTC) and to investigate the possible mechanism underlying this disease. The gene expression profile, GSE53157, was downloaded from the Gene Expression Omnibus database. Only 10 chips, including 3 specimens of normal thyroid tissues and 7 specimens of well-differentiated thyroid carcinomas, were analyzed in the present study. Differentially-expressed genes (DEGs) between PTC patients and normal individuals were identified. Next, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses of DEGs were performed. Modules in the protein-protein interaction (PPI) network were identified. Significant target genes were selected from the microRNA (miRNA) regulatory network. Furthermore, the integrated network was constructed with the miRNA regulatory and PPI network modules, and key target genes were screened. A total of 668 DEGs were identified. Modules M1, M2 and M3 were identified from the PPI network. From the modules, DEGs of cyclin-dependent kinase inhibitor 1A, S100 calcium binding protein A6 (S100A6), dual specificity phosphatase 5, keratin 19, met proto-oncogene (MET) and lectin galactoside-binding soluble 3 were included in the Malacards database. In the miRNA regulatory and integrated networks, genes of cyclin-dependent kinase inhibitor 1C (CDKN1C), peroxisome proliferator-activated receptor γ, aryl hydrocarbon receptor, basic helix-loop-helix family, member e40 and reticulon 1 were the key target genes. S100A6, MET and CDKN1C may exhibit key roles in the progression and development of PTC, and may be used as specific therapeutic targets in the treatment of PTC. However, further experiments are required to confirm these results.
Insights
This study identified key genes like S100A6, MET, and CDKN1C as potential therapeutic targets for papillary thyroid carcinoma (PTC). These findings offer new insights into PTC mechanisms and treatment strategies.
Area of Science:
- Oncology
- Genomics
- Bioinformatics
Background:
- Papillary thyroid carcinoma (PTC) is a common endocrine malignancy.
- Understanding the molecular mechanisms of PTC is crucial for developing effective therapies.
Purpose of the Study:
- To identify novel therapeutic targets for PTC.
- To elucidate the underlying molecular mechanisms of PTC development.
Main Methods:
- Downloaded and analyzed gene expression profile (GSE53157) from the Gene Expression Omnibus database.
- Identified differentially-expressed genes (DEGs) between PTC and normal thyroid tissues.
- Performed Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses.
- Constructed protein-protein interaction (PPI) and microRNA (miRNA) regulatory networks.
- Integrated PPI and miRNA networks to identify key target genes.
Main Results:
- Identified 668 DEGs between PTC and normal tissues.
- Selected key target genes including S100 calcium binding protein A6 (S100A6), met proto-oncogene (MET), and cyclin-dependent kinase inhibitor 1C (CDKN1C).
- S100A6, MET, and CDKN1C were implicated in PTC progression and development.
Conclusions:
- S100A6, MET, and CDKN1C represent potential specific therapeutic targets for PTC.
- Further experimental validation is necessary to confirm these findings and their therapeutic utility.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Targeted Cancer Therapies
There are several types of targeted therapies against...

